Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service
Intention to award the Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service. <br/><br/>This is a a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained...
Buyer
NHS England
Value
£26,136,000
Published
4 Jun 2026
Closes
8 Jul 2026
Procurement details
Source
Find a Tender
Region
London
Procurement method
Open
Category
Services
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
85100000
Health services
Lots
Lot 0 Lot 1
£8,527,000
Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)
Delivery: United Kingdom
Lot 3 Lot 3
£8,283,000
Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2) Additional information: Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)
Delivery: United Kingdom
Lot 1 and 2 Lots 3
£9,326,000
Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)
Delivery: United Kingdom
Lot 1 Lot 1
Value not provided
Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)
Delivery: United Kingdom
Lot 2 Lot 2
Value not provided
Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)
Delivery: United Kingdom
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.